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Abstract
During mammalian palatal fusion, the medial edge epithelial (MEE) cells must stop DNA synthesis prior to the initial contact of opposing
palatal shelves and thereafter selectively disappear from the midline. Exogenous EGF has been shown to inhibit the cessation of DNA
synthesis and induce cleft palate; however, the precise intracellular mechanism has not been determined. We hypothesized that EGF
signaling acting via ERK1/2 would maintain MEE DNA synthesis and cell proliferation and consequently inhibit the process of palatal
fusion. Palatal shelves from E13 mouse embryos were maintained in organ cultures and stimulated with EGF. EGF-treated palates failed
to fuse with intact MEE and had significant ERK1/2 phosphorylation. Both EGF-induced ERK1/2 phosphorylation and BrdU-incorporation
were localized in the nucleus of MEE cells. Subsequent inhibition assays using U0126, a specific inhibitor of ERK1/2 phosphorylation, were
conducted. U0126 inhibited EGF-induced ERK1/2 phosphorylation in a dose-dependent manner and consequently MEE cells stopped
proliferation. The threshold of ERK1/2 inactivation to stop MEE DNA synthesis coincides with the level required to rescue the EGF-induced
cleft palate phenotype. These results indicate that EGF-induced inhibition of palatal fusion is dependent on nuclear ERK1/2 activation and
that this mechanism must be tightly regulated during normal palatal fusion.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Development of the mammalian secondary palate is a
complex process, which is frequently disturbed, resulting in
cleft palate, a common human birth defect (Ferguson, 1988,
1994). Palatal fusion requires that the medial edge epithe-
lium (MEE) disappear from the midline to permit mesen-
chymal confluence. Multiple mechanisms for the disappear-
ance of MEE have been shown, including programmed cell
death, epithelial–mesenchymal transformation, and migra-
tion to adjacent epithelia (Shuler, 1995). These three mech-
anisms would be differently affected by either genetic or
environmental factors that might induce cleft palate
(Schutte and Murray, 1999; Young et al., 2000).
Although distinctly different molecular changes would
be associated with the three mechanisms for MEE removal,
there is agreement that MEE cells stop DNA synthesis prior
to the initial contact of opposing palatal shelves (Greene and
Pratt, 1976; Hudson and Shapiro, 1973; Pratt and Martin,
1975). The cessation of DNA synthesis in the MEE may be
related to the induction of new patterns of gene transcription
required for new cell fates. Several growth factors have
been reported to influence the complex events during pal-
atogenesis (Ferguson, 1988; Greene, 1989). Among them,
epidermal growth factor (EGF) has been shown to inhibit
the cessation of MEE DNA synthesis and induce cleft palate
(Abbott et al., 1988; Hassell, 1975; Tyler and Pratt, 1980).
When exogenous EGF is administered in sufficient doses to
cause teratogenesis, MEE cells maintain DNA synthesis and
cell proliferation with consequent failure to undergo the
process of normal palatal fusion. Supportive evidence indi-
cated that EGF signaling is involved in mechanisms of
teratogen-induced cleft palate, particularly with 2,3,7,8-tet-
rachlorodibenzo-p-dioxin (TCDD) (Abbott and Birnbaum,
1989) and retinoic acid (RA) (Abbott et al., 1988). EGF
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signaling through an intracellular signaling pathway may
alter patterns of gene expression crucial to palatogenesis.
The EGF signaling pathway is expressed in many organs
whose development is dependent on epithelial–mesenchy-
mal interactions, and EGF has a crucial role in the regula-
tion of cell proliferation and differentiation (Fisher and
Lakshmanan, 1990; Pratt, 1987; Thesleff et al., 1995). The
binding of EGF to its receptor activates the receptor tyrosine
kinase (RTK) with concomitant tyrosine autophosphoryla-
tion (Hackel et al., 1999). Although the activation leads to
variety of downstream effects (Moghal and Sternberg,
1999), the most essential pathway for EGF-induced cell
proliferation is an extracellular signal-regulated kinase
(ERK), referred to as the mitogen-activated protein kinase
(MAPK) (Graves et al., 2000; Marshall, 1995). The ERK
pathway is composed of a module of three kinases: Raf/
MEK/ERK, consisting of MAPK kinase kinase (MAPKKK;
Raf), which phosphorylates and activates MAPK kinase
(MAPKK; MEK1/2), which in turn phosphorylates and ac-
tivates MAPK (ERK1/2). This signaling cascade progresses
by the sequential phosphorylation and activation of the
components, ultimately leading to the phosphorylation of a
conserved Thr-X-Tyr motif of ERK1/2 (Kolch, 2000).
ERK1/2 are the only known substrates of MEK1/2 and are
not activated by other MAPKK (Pearson et al., 2001). The
activated ERK1/2 are translocated from the cytoplasm to the
nucleus where they phosphorylate and activate nuclear tran-
scription factors leading to changes in target gene expres-
sion (Brunet et al., 1999; Khokhlatchev et al., 1998). Acti-
vation of this cascade occurs rapidly and ERK1/2 activation
is maximal by 30 min after binding of ligand to RTK,
suggesting the presence of a feedback loop to regulate
activation (Marshall, 1995; Waterman and Yarden, 2001).
We hypothesized that EGF signaling acting via ERK1/2
would maintain MEE DNA synthesis and cell proliferation
and consequently inhibit the process of palatal shelf fusion.
Additional evidence supports this hypothesis since RTK-
ERK1/2 signaling is shared with several factors, such as
insulin growth factor (IGF) and integrin (Schlessinger,
2000; Schwartz and Ginsberg, 2002), whose upregulation is
involved in cleft palate (Eggenschwiler et al., 1997; Tudela
et al., 2002). These facts suggest that ERK1/2 signaling may
have a crucial role in the molecular control of palatal fusion.
The series of developmental events that are necessary for
palatal fusion have been shown to be similar both in vivo
and in an organ culture model of palatal fusion in vitro (Cui
and Shuler, 2000; Shuler et al., 1991, 1992). Thus, we used
the palate organ culture system to further investigate the
effects of exogenous growth factors. To investigate the role
of ERK1/2 signaling during EGF-induced inhibition of pal-
atal fusion, we examined the expression levels and subcel-
lular localizations of phosphorylated forms of ERK1/2 pro-
teins and cell proliferation using BrdU-incorporation in the
presence or absence of a specific inhibitor for ERK1/2
signaling.
Materials and methods
Palatal shelf organ culture
Palatal shelves were cultured according to the methods
previously described (Cui and Shuler, 2000; Shuler et al.,
1991). Briefly, timed pregnant Swiss-Webster mice were
sacrificed on embryonic day 13 (E13). Palatal shelves were
dissected from the fetal murine heads under sterile condi-
tions and placed in pairs on Millipore filters with correct
anterior–posterior orientation and their medial edges in con-
tact to minimize differences in growth rate in the midline.
The palatal shelves were cultured by using Trowell organ
culture dishes in BGJb medium (GIBCO, Grand Island,
NY) at 37°C in 5% CO2. The cultures were treated with
recombinant human EGF (R&D Systems, Minneapolis,
MN), whereas control cultures were untreated. To deter-
mine the effects of EGF dose on ERK1/2 phosphorylation,
cultures were treated with different doses of EGF up to 100
ng/ml for 30 min. Immunoblotting (see next description)
demonstrated that EGF induced ERK1/2 phosphorylation in
a dose-dependent manner with a peak at 50 ng/ml EGF (Fig.
1A and B). The 50-ng/ml concentration of EGF was used
for every experiment, and EGF was added to the media
throughout the culture periods. The culture media was
changed every 24 h respectively and cultures were main-
tained for up to 72 h.
For proliferation assays, the cultures were treated with
5-bromo-2-deoxyuridine (BrdU) (100 M) (Sigma, St.
Louis, MO) for 2 h before the collection of cultures, and
incorporation of BrdU was examined in both EGF treated
and untreated cultures.
For inhibition assays, the palatal shelves were preincu-
bated with U0126 (specific inhibitor for phosphorylation
and activation of MEK1/2) (Favata et al., 1998; Kling et al.,
2002) (Cell Signaling, Beverly, MA) for 2 h before addition
of EGF. Control cultures, without the inhibitor added, were
supplemented with an equivalent volume of dimethylsulf-
oxide (DMSO; the recommended solvent for U0126).
Immunoblotting
Quantitative protein analysis was performed by using
sodium dodecylsulfate polyacrylamide gel electrophoresis
(SDS-PAGE) and Western blotting following the standard
method for the BM Chemiluminescence Blotting Kit
(Roche, Indianapolis, IN). At the end of each culture period,
the middle region of each pair of palatal shelves was dis-
sected to minimize contamination with mesenchymal cells
or tooth bud. The tissue from a single pair of palates was
homogenized for each sample at 85°C in lysis buffer (50
mM Tris–HCl, 2% SDS, 10% glycerol). The homogenates
were then boiled for 10 min, centrifuged, and the superna-
tants were recovered for determination of protein content by
using DC Protein Assay Kit (Bio-Rad Labs, Hercules, CA).
For each lane, 25 g (20 g for inhibition assays) of protein
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was resolved by 12% SDS-PAGE and electroblotted onto
polyvinylidene difluoride membrane (Roche). The blots
were then blocked for 1 h at room temperature with supplied
1% blocking solution (Roche) in Tris-buffered saline and
incubated overnight at 4°C with a 1:1000 dilution of poly-
clonal antibodies specific to phospho-ERK1/2 or total
(phosphorylation state-independent)-ERK1/2 (both antibod-
ies from Cell Signaling). The blots were exposed to horse-
radish peroxidase (HRP)-conjugated goat anti-rabbit IgG
for 30 min at room temperature and reacted with substrate
(Luminol/H2O2) according to the manufacturer’s protocol.
The signal intensities were quantitated by densitometric
analysis using IMAGE QUANT (Molecular Dynamics,
Sunnyvale, CA). The data were presented as mean  stan-
dard deviation (SD) and analyzed for statistically significant
differences by two-tailed paired Student’s t test. Values of P
 0.01 were considered significant.
Specimen preparation
For immunohistochemistry, palatal organ cultures were
obtained at the end of each culture period, then fixed im-
mediately in 4% paraformaldehyde-phosphate buffer saline
(PBS) at 4°C, immersed in sucrose-PBS gradually up to
18%, and embedded in OCT compound to cut cryosections
(8 m thick). For proliferation assays, cultures were fixed
with 10% neutral buffered formalin followed by routine
procedures to prepare paraffin serial sections (5 m thick).
All embedded specimens were cut perpendicular to the
anterior–posterior axis of the pair of palatal shelves, and the
sections were mounted on poly-L-lysine (Sigma) coated
slides. Counterstain was performed with hematoxylin.
Immunohistochemistry
The fresh cryosections were briefly fixed in 100% ace-
tone and air dried. The sections were heated in citrate buffer
for epitope retrieval. To inactivate endogenous peroxidase,
the sections were incubated with Peroxo-Block (Zymed,
South San Francisco, CA). Nonspecific background was
eliminated by incubating with nonimmune goat serum. The
sections were then incubated overnight at room temperature
with a 1:25 dilution of phospho-ERK1/2 antibody (Cell
Signaling). The incubations were followed by addition of
biotinylated goat anti-rabbit IgG. Streptavidin–peroxidase
was used as a signal generator, and the procedure was
completed by using aminoethyl carbazole/H2O2 as a
chromagen (HISTOSTAIN Kit; Zymed).
MEE cell proliferation assay
Incorporation of BrdU was analyzed to examine the
patterns of MEE proliferation (cells in S-phase of the cell
cycle). The paraffin sections were deparaffinnized and re-
hydrated. Endogenous peroxidase activity was quenched by
treatment with 3% hydrogen peroxide in methanol. Epitope
Fig. 1. EGF induced ERK1/2 phosphorylation. Immunoblotting was per-
formed on protein extracts (25 g for each lane) from the palate organ
cultures. The immunoblots present phosphorylated ERK1/2 (P-ERK) and
total (phosphorylation-independent) ERK1/2 (T-ERK). (A) Dose-depen-
dent EGF induced ERK1/2 phosphorylation. E13 palatal shelves were
treated without EGF (0) or with EGF 10 ng/ml (10), 50 ng/ml (50), or 100
ng/ml (100) for 30 min. The immunoblot showed that EGF-induced P-ERK
peaked at 50 ng/ml (**). (B) P-ERK and T-ERK signals were quantitated
by densitometric analysis. Data are presented as mean  SD (n  3). **,
P  0.005 for P-ERK quantity with 50 ng/ml EGF. (C) EGF induced
ERK1/2 phosphorylation at three culture times. E13 palatal shelves were
treated with EGF (50 ng/ml) (E), and control cultures were untreated (C).
The cultures were collected every 24 h (24, 48, 72) for the analysis. (D)
P-ERK and T-ERK were quantitated by densitometric analysis. Data are
presented as mean  SD (n  8). *, P  0.01; **, P  0.005 for ERK
activity with EGF vs control.
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retrieval and blocking were performed as previously de-
scribed. The sections were then incubated with biotinylated
mouse anti-BrdU monoclonal antibody. Streptavidin–per-
oxidase was used as a signal generator, and the procedure
was completed by using diaminobenzidine/H2O2 as a
chromagen (BrdU STAINING Kit, Zymed).
Results
Cultures were analyzed at the developmental stages de-
termined by previous studies (Cui and Shuler, 2000; Shuler
et al., 1991). The analysis was performed at three key stages
that match in vivo stages of palatal development: (1) 24 h of
organ culture (equivalent to E14), when palatal shelves
become adherent and an epithelial seam forms in the mid-
line; (2) 48 h of organ culture (equivalent to E15), when the
midline seam becomes fragmented with some MEE remain-
ing as epithelial islands; and (3) 72 h of organ culture
(equivalent to E16), when palatal fusion was complete with
disappearance of MEE throughout the entire palate. We
completed every experiment according to this time sched-
ule, and all experiments were completed in triplicate.
EGF inhibited palatal fusion
To determine the effect of EGF treatment for palatal
fusion, EGF-treated and untreated palatal shelves were ex-
amined histologically after 72 h of palate organ culture
(Table 1). The temporal sequences in the process of palatal
fusion were highly reproducible in the organ culture model.
Control palate organ cultures fused completely, the shelves
became continuous, and MEE disappeared completely
(100%). EGF-treated palatal shelves had MEE that were
adherent; however, it was evident that the process of MEE
contact alone was not sufficient to initiate the breakdown of
the midline seam (Ferguson, 1988). The midline epithelial
seam was intact with either two-cell layer-thick (95%) or
fragmented (5%) of MEE, indicating that EGF effectively
inhibited palatal fusion.
EGF-induced ERK1/2 phosphorylation in palatal shelves
EGF-induced ERK1/2 phosphorylation was examined at
each culture point by using SDS-PAGE and western blot-
ting (Fig. 1C). Control cultures had only low levels of the
phosphorylated forms of ERK1/2 (P-ERK), representing the
endogenous amount of P-ERK. In contrast, EGF-treated
cultures had markedly higher levels of P-ERK. Total
ERK1/2, including both phosphorylated and nonphospho-
rylated forms of ERK1/2 (T-ERK), was present at the same
level in both EGF-treated and control palate tissue, indicat-
ing that ERK1/2 activation was not attributable to upregu-
lation of T-ERK synthesis. The signal intensity of each band
was quantitated by densitometric analysis, and all data were
analyzed statistically. EGF-induced ERK1/2 phosphoryla-
tion was significantly increased at every culture point (Fig.
1D).
Active ERK was translocated to the nucleus in MEE cells
The subcellular localizations of P-ERK were identified
by immunohistochemistry (Fig. 2). P-ERK was localized
predominantly in the epithelia covering the palatal shelves,
oral, nasal epithelium, and MEE, but not in palatal mesen-
chyme. This epithelial-specific pattern of P-ERK was con-
stant at every culture time point examined. EGF-treated
palatal organ cultures appeared to be arrested at intermedi-
ate stages of palatogenesis characteristic of E14 and there
was sustained P-ERK expression in MEE cells. P-ERK was
primarily localized in the nucleus of MEE cells and the
P-ERK was translocated to the nucleus in response to longer
periods of EGF stimulation (Fig. 2A–C). Palates without
adhesion even after 72 h of culture had high levels of
P-ERK in the nucleus of the MEE (Fig. 2G). The expression
of P-ERK in control cultures after 24 h of culture was
primarily in the cytoplasm and was much less common in
the nucleus of the MEE (Fig. 2D). The P-ERK was mark-
edly diminished following MEE disruption (Fig. 2E and F)
and the P-ERK nuclear staining was absent in the disrupted
midline seam (Fig. 2E). These results indicated that ERK1/2
were activated in response to EGF stimulation, and the
phosphorylated forms were translocated from the cytoplasm
to the nucleus in the MEE.
EGF maintained MEE cell proliferation
To determine whether EGF induces MEE DNA synthe-
sis, we cultured palatal shelves with BrdU for 2 h before the
collection of cultures and the incorporation of BrdU in MEE
DNA was analyzed (Fig. 3). BrdU-incorporation was pre-
dominantly localized in the epithelium and was increased in
EGF-treated cultures. The incorporation was identified in
the nucleus of MEE cells in every EGF-treated culture (Fig.
3A–C), indicating that EGF maintained MEE DNA synthe-
sis and cell proliferation. This BrdU localization was similar
to the nuclear localization of P-ERK previously described.
In control cultures, BrdU-incorporation was uncommon
when compared with the EGF-treated cultures. Most MEE
had no incorporation during the initial contact of opposing
palatal shelves as observed during in vivo palatal fusion
Table 1
Residual MEE in palatal shelf after 72 h of culture
EGF (50 ng/ml) Control
Number of palates 38 31
without adhesion 11/38 (29%) 0/31 (0%)
with intact MEE 25/38 (66%) 0/31 (0%)
with fragmented MEE 2/38 (5%) 0/31 (0%)
without MEE 0/38 (0%) 31/31 (100%)
Note. Palates with intact two layers of MEE and palates with some
discontinuous areas of MEE were scored separately. MEE, medial edge
epithelium.
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(Fig. 3D), and no BrdU-positive MEE were present during
the disappearance of the midline epithelial seam (Fig. 3E
and F).
U0126 rescued the EGF-induced cleft palate phenotype
Inhibition assays were performed by using U0126, a
specific inhibitor for MEK1/2 (Favata et al., 1998; Kling et
al., 2002), to directly address whether ERK1/2 phosphory-
lation was required for EGF-induced inhibition of palatal
fusion. Cultures were maintained for 72 h to examine P-
ERK expression and BrdU-incorporation and to evaluate
their distribution in the MEE. To test the specificity of
U0126, we treated cultures with a high dose of the inhibitor
(50 M) in either the presence or absence of EGF (Fig. 4A).
The cultures treated with both U0126 and EGF had low
levels of P-ERK similar to the endogenous levels in control
cultures treated with neither U0126 nor EGF. U0126 com-
pletely inhibited P-ERK expression in control cultures with-
out EGF. To determine the effects of U0126 dose for EGF-
Fig. 2. Subcellular localization of phosphorylated ERK1/2 E13 palatal shelves were cultured with EGF (50 ng/ml) (A–C, G), and control cultures were
untreated (D–F). The cultures were collected every 24 h; E13  24h (A, D), E13  48h (B, E), and E13  72h (C, F, G). The localization of phosphorylated
ERK1/2 (P-ERK) was determined by using anti-phospho-ERK1/2 antibody. High magnification of MEE is presented to the right of each panel. P-ERK was
primarily localized in the nucleus of the MEE of EGF treated cultures and translocated to the nucleus following prolonged EGF stimulation (A–C, G). P-ERK
in control cultures was in the cytoplasm and much less common in the nucleus of the MEE. P-ERK was markedly diminished following MEE disruption
(D–F). Scale bars: 50 m for low magnification; 10 m for high magnification.
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induced inhibition of palatal fusion, cultures were treated
with different doses of U0126 up to 75 M. U0126 inhib-
ited ERK1/2 phosphorylation in a dose-dependent manner.
No significant expression of P-ERK was observed in the
presence of 75 M U0126 (Fig. 4B). We found that 10 M
U0126 was not sufficient to rescue the cleft palate pheno-
type in EGF treated palatal cultures, even though 10 M
U0126 caused a decrease in the P-ERK levels (Fig. 4C). The
cultures treated with 10 M U0126 had a largely intact
two-layer seam of MEE (100%; Table 2) and both P-ERK
expression and BrdU-incorporation were positive in MEE
cells (Fig. 5A and E). Cultures treated with 25 or 50 M
U0126 had low levels of P-ERK (Fig. 4B), and histologic
examination of specimens revealed that there was a normal
pattern of palatal fusion; palatal shelves were fused histo-
logically and MEE completely disappeared (25 M: 50%,
50 M: 67%; Table 2). Palatal shelf cultures treated with
either 25 or 50 M U0126 were indistinguishable from the
control cultures and both P-ERK expression and BrdU-
incorporation resembled control cultures (Fig. 5C and G;
Figs. 2F and 3F). Exogenous EGF had no effect on palatal
fusion under the U0126 treatment conditions; thus, U0126
rescued the EGF-induced cleft palate phenotype. A total of
75 M U0126 inhibited both ERK1/2 phosphorylation and
BrdU-incorporation throughout the entire palate (Fig. 5D
and H), but while MEE were absent from the midline, the
mesenchyme demonstrated some discontinuity in that re-
gion (Fig. 5H, arrows).
Discussion
To date, three distinct mammalian MAPKs have been
characterized: ERK1/2, c-jun amino-terminal kinases
(JNK), and p38 proteins (Chang and Karin, 2001). It is
generally accepted that ERK1/2 are preferentially activated
in response to growth factors associated with cell prolifer-
ation and differentiation, while the JNK and p38 MAPKs
are strongly activated by environmental and genotoxic
stresses (Pearson et al., 2001). To identify the intracellular
signaling pathways involved in palatogenesis, we have
shown that EGF is an inducer of ERK1/2 phosphorylation in
the MEE. EGF-treated cultures had increased levels of P-
ERK when compared with the endogenous P-ERK in con-
trol cultures. Furthermore P-ERK was localized at its ex-
pected subcellular sites. In EGF-treated cultures, P-ERK
was activated and translocated from the cytoplasm to the
nucleus in the MEE, which is required for growth factor-
induced gene expression and cell cycle entry (Brunet et al.,
1999; Khokhlatchev et al., 1998). Indeed, remarkably high
Fig. 3. EGF maintained MEE DNA synthesis. E13 palatal shelves were cultured with EGF (50 ng/ml) (A–C), whereas control cultures were untreated (D–F).
Every culture was treated with BrdU (100 M) for 2 h before the specimen collection: E13  24h (A, D), E13  48h (B, E), and E13  72h (C, F). The
incorporation of BrdU was examined by using anti-BrdU antibody. EGF-treated cultures had BrdU-positive cells in MEE continuously (A–C), whereas
control cultures had no BrdU-positive MEE (D–F). Scale bars: 50 m.
517T. Yamamoto et al. / Developmental Biology 260 (2003) 512–521
levels of the BrdU-incorporation were observed in the MEE
of EGF-treated cultures corresponding to the expression of
P-ERK. These results indicated that the MEE was main-
tained in a proliferative state following EGF-induced nu-
clear ERK1/2 activation. In control cultures, P-ERK was
present only in the cytoplasm and was less common in the
nucleus. MEE in control cultures did not incorporate BrdU,
providing supportive evidence of the dependency of nuclear
ERK1/2 activation for continued MEE proliferation. Cells
can exhibit either a proliferative or differentiative response
following RTK activation on the basis of the duration and
localization of ERK1/2 phosphorylation (Marshall, 1995;
Pouyssegur et al., 2002). Evidence exists that the retention
of phosphorylated ERK1/2 in the cytoplasm would be suf-
ficient to block cell proliferation (Brunet et al., 1999; Form-
stecher et al., 2001; Tohgo et al., 2002). Thus, the cytoplas-
mic ERK1/2 activation in the MEE during normal palatal
fusion might play a crucial role in the MEE differentiation
critical to complete palatal fusion.
To more directly address whether ERK1/2 phosphoryla-
tion was required for EGF-induced inhibition of palatal
fusion, we performed inhibition assays using a specific
inhibitor of MEK1/2 (U0126) to eliminate the ERK1/2
phosphorylation with only minimal alterations of other ki-
nase pathways (Favata et al., 1998; Kling et al., 2002). In
the presence of either 25 or 50 M U0126, EGF-induced
ERK1/2 phosphorylation was decreased to control levels
accompanied by a marked reduction of BrdU-incorporation
in MEE cells and restoration of the palatal shelves to a
normal stage of fusion. The inhibitor of ERK1/2 phosphor-
ylation led to a cessation of MEE DNA synthesis in EGF-
induced MEE, and subsequently the MEE disappeared from
the midline to allow confluence of the mesenchyme. EGF
signaling can activate a variety of downstream effectors,
including JNK, p38 MAPKs, phospholipase C1 (PLC1),
and phosphatidylinositol 3-kinase (PI3K) (Moghal and
Sternberg, 1999). However, as demonstrated by these
U0126 inhibition assays, the reduction of BrdU-incorpora-
tion in the MEE and MEE disappearance were dependent on
the level of ERK1/2 phosphorylation. Thus, our study indi-
cated that EGF-induced MEE cell proliferation and inhibi-
tion of palatal fusion were dependent on ERK1/2 phosphor-
ylation but not other kinase pathways. Interestingly, 75 M
U0126, while inhibiting both ERK1/2 phosphorylation and
BrdU-incorporation and permitting MEE disappearance
from the midline, was associated with a discontinuity of the
mesenchyme in the region, suggesting that high concentra-
tions of the inhibitor may be toxic to palatal tissues. ERK1-
deficient mice were developmentally normal except for al-
tered thymocyte maturation (Pages et al., 1999) and
modified behavioral responses (Mazzucchelli et al., 2002);
thus, ERK2, which was more abundant in palate, might have
a more important role in palatogenesis. Another animal
model (Egfr/: epidermal growth factor receptor- defi-
cient) provided evidence that EGF signaling is important in
palatogenesis (Miettinen et al., 1999). The (Egfr/) mice
had mandibular malformations resulting from decreased
matrix metalloproteinase (MMP) activity and palatal
shelves in organ culture had fragmented residual MEE. We
Fig. 4. U0126 inhibited ERK1/2 phosphorylation. Cultures were preincu-
bated with U0126 for 2 h prior to addition of EGF (50 ng/ml). Control
cultures, without the U0126 added, were supplemented with an equivalent
volume of DMSO solvent. The cultures were maintained for 72 h and
collected for immunoblotting by using protein extracts (20 g for each
lane) from the cultures. The immunoblots demonstrate phosphorylated
ERK1/2 (P-ERK) and total (phosphorylation-independent) ERK1/2 (T-
ERK). (A) U0126 inhibited both endogenous and exogenous P-ERK.
Cultures were treated without EGF (lanes 1 and 3) or with EGF (lanes 2
and 4) in the absence (lanes 1 and 2) or presence (lanes 3 and 4) of 50 M
U0126. Data shown are representative of three separate experiments. (B)
U0126 inhibited P-ERK expression in EGF-treated cultures in a dose-
dependent manner. Every culture was treated with EGF in the absence (0)
or presence of different doses of U0126 up to 75 M/ml (10, 25, 50, 75).
(C) P-ERK and T-ERK signals were quantitated by densitometric analysis.
Data are presented as mean  SD (n  5). **, P  0.005 for ERK activity
with 0 M/ml vs 10 M/ml and 10 M/ml vs 25 M/ml of U0126,
respectively.
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speculate that the (Egfr/) phenotype, inhibition of palatal
fusion, could be attributed to MMP dysfunction.
It has already been shown that transforming growth fac-
tor 3 (TGF3) is crucial for palatal fusion (Kaartinen et
al., 1995, 1997; Proetzel et al., 1995). Components of the
EGF and TGF signaling pathways may interact in control-
ling cell proliferation and differentiation. TGF can over-
ride the proliferative effects of EGF in normal epithelial
cells (Like and Massague, 1986; Massague, 1990). How-
ever, at high levels of EGF signaling, the antiproliferative
effects of TGF can be prevented by activated ERK1/2
(Gehris et al., 1994; Kretzschmar et al., 1999; Massague and
Chen, 2000). This mechanism might be applicable to EGF-
induced cleft palate. During normal palatal fusion, TGF
could inhibit the translocation of active ERK1/2 and over-
ride the proliferative effects of endogenous EGF to com-
plete MEE disappearance. However, exogenous EGF ad-
ministered in large doses would activate ERK1/2 that could
override the antiproliferative effects of TGF and conse-
quently the MEE would maintain cell proliferation and fail
to undergo the events critical to the process of normal
palatal fusion. Thus, MEE cell proliferation might be de-
Table 2
Residual MEE in palatal shelf after 72 h of culture with either EGF or U0126
EGF      
U0126   U0126 (M/ml)
10 25 50 75
Number of palates 6 9 9 14 15 10
with no MEE 6/6 (100%) 0/0 (0%) 0/0 (0%) 7/14 (50%) 10/15 (67%) 7/10 (70%)
with fragmented MEE 0/0 (0%) 0/0 (0%) 9/9 (100%) 7/14 (50%) 5/15 (33%) 3/10 (30%)
with intact MEE 0/0 (0%) 9/9 (100%) 0/0 (0%) 0/0 (0%) 0/0 (0%) 0/0 (0%)
Note. An equivalent volume of DMSO was added to the cultures not treated with U0126. MEE, medial edge epithelium.
Fig. 5. Reduction of MEE cell proliferation and MEE disappearance are dependent on ERK1/2 phosphorylation. E13 palatal shelves were preincubated with
U0126; 10 M (A, E), 25 or 50 M (B, C, F, G), 75 M (D, H) for 2 h prior to addition of EGF (50 ng/ml). The cultures were maintained for 72 h and
collected for immunohistochemical analysis by using anti-phospho-ERK1/2 antibody (A–D). For proliferation assays, cultures were treated with BrdU (100
M) for 2 h before the collection. The incorporation of BrdU was examined by using anti-BrdU antibody (E–H). The cultures treated with 10 M U0126
palatal shelves had largely intact two-cell layer-thick MEE in the midline, and both phosphorylated ERK1/2 (P-ERK) and BrdU-incorporation were positive
in the MEE (A, E). Cultures treated with 25 or 50 M U0126 had fragmented MEE with reduced P-ERK and BrdU-incorporation (B, F), palatal shelves fused
histologically, and MEE disappeared (C, G). A total of 75 M U0126 inhibited both P-ERK and BrdU-incorporation throughout the entire palate (D, H).
Although MEE disappeared from the midline, the mesenchyme was discontinuous in the region (H, arrows). Scale bars: 50 m.
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pendent on the relative strengths of competing EGF and
TGF signaling. Slight shifts in either EGF or TGF effects
could alter patterns of gene expression in the MEE, thereby
changing the differentiation of the cells altering critical
events in the midline seam. The in vivo incorporation of
BrdU in the MEE of TGF3 null mice further supports this
concept and the frequency of BrdU-positive cells in the
MEE was significantly less in wild-type when compared
with TGF3 null mutant mice (Cui et al., 2003). The exact
relationships between EGF and TGF3 signaling pathways
during palatogenesis require further examination.
In summary, our studies provide evidence for a critical
role of ERK1/2 signaling during EGF-induced inhibition of
palatal fusion. The findings of this study clearly establish
that active ERK1/2 is present in the MEE nuclei of EGF-
treated palate organ cultures and that inhibition of MEE
proliferation and subsequent MEE disappearance is depen-
dent on the level of ERK1/2 phosphorylation. These results
point to a tight regulatory relationship between ERK1/2
phosphorylation and the molecular control of palatogenesis.
We propose that EGF signaling acting via ERK1/2 is main-
tained within a physiologically appropriate level during
normal palatal fusion and propose that activation of ERK1/2
to inappropriately high levels might contribute to the etiol-
ogy of cleft palate.
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